MacroGenics, I-Mab team up to develop & market enoblituzumab in China
Category: #health  By Pankaj Singh  Date: 2019-07-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

MacroGenics, I-Mab team up to develop & market enoblituzumab in China

MacroGenics, Inc. and I-Mab Biopharma, a U.S. and China based clinical-stage biopharmaceutical company that is committed to discover and develop biologics in autoimmune and immune-oncology diseases, have recently announced that they have inked an exclusive license agreement through which the companies will collaborate to develop and commercialize enoblituzumab.

Apparently, the investigational drug is anti-B7-H3, an immune-optimized, monoclonal antibody which incorporates proprietary Fc Optimization tech platform of MacroGenics. Enoblituzumab is among the most advanced development programs directed against B7-H3 under development, as not agent has been approved yet for the target. The regional development and commercialization rights are now owned by I-Mab for Hong Kong, Taiwan, Macau and China.

According to sources, I-Mab will be participating in the global studies conducted by MacroGenics, besides leading the regional studies as part of the collaboration. MacroGenics will be initiating enoblituzumab’s Phase 2 study combined with MGA012, an anti-PD-1 antibody which MacroGenics has licensed to Incyte Corporation, in patients with neck and head cancer later in the year.

President and CEO of MacroGenics, Scott Koenig, M.D., Ph.D., said that the company is looking forward to working with I-Mab and the partnership will broaden and accelerate the enoblituzumab development as well as support the company’s mission to bring innovative medicines to patients having unmet medical needs.

Owing to I-Mab’s track record of quickly progressing immuno-oncology programs and its ability to reach into the expanding pharmaceutical market in the region, the company believes it to be an ideal partner, Koenig added.

Reportedly, the collaboration will fetch MacroGenics an upfront payment of $15 million. It will also benefit from the eligibility to receive additional payments of $135 million for development and regulatory milestones. Additionally, I-Mab will be expected to pay tiered double-digit royalties of up to twenty percent, based on the net territory sales annually.

Source Credit- http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-and-i-mab-announce-exclusive-collaboration-and



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...